- Altos Labs – a $3 billion biotech startup backed by Jeff Bezos – is on a mission to restore cell health and reverse diseases by rejuvenating cells . It launched in 2022 with a dream of extending healthy human lifespan.
- Not about “cheating death”: Altos’s president Hans Bishop insists the focus is on extending “healthspan” (years of healthy life), with any longevity gains merely an “accidental consequence” fightaging.org. The company emphasizes improving life quality over pursuing immortality.
- Unprecedented talent & funding: Altos assembled a “dream team” of scientists – including Nobel laureate Shinya Yamanaka – by offering academic freedom and industry-level resources. Led by former GSK executive Hal Barron as CEO, and co-founded by biotech veterans Richard Klausner and Hans Bishop, Altos attracted $3 billion from prominent investors (Bezos, Yuri Milner, Arch Ventures) labiotech.eu en.wikipedia.org, making it one of the best-funded startups in biotech history.
- Racing a booming longevity industry: Altos Labs is part of a broader anti-aging biotech boom. Alphabet’s Calico Labs (launched 2013) was a pioneer, and newer startups like Retro Biosciences and Loyal have joined the fray – all aiming to extend healthy lifespan via cutting-edge science and drawing investments from Silicon Valley billionaires .
- Innovations in “rejuvenation” science: Altos and its peers are leveraging breakthroughs like partial cellular reprogramming – using Yamanaka factors to reset adult cells to a youthful state – which has shown promise in animals labiotech.eu labiotech.eu. Other approaches include senolytic drugs to clear aged “zombie” cells and gene therapies, all targeting aging at its biological roots.
- Early results signal hope: In 2024, Altos scientists published a landmark study demonstrating that partial reprogramming extended the lifespan of mice and improved health markers . This evidence that aging may be reversible has been hailed as a major step toward translating rejuvenation technologies to humans.
- Competition and collaboration: Companies like Retro Biosciences (funded by OpenAI’s Sam Altman) aim to add 10+ years to human life through cell reprogramming and autophagy, planning their first clinical trials and reportedly seeking $1 billion for next steps . Loyal, which has raised over $125 million, is developing drugs to extend dogs’ lifespans as a springboard to human applications – and expects to launch the first FDA-approved longevity drug for pets by 2025
Inside Altos Labs: Jeff Bezos’s $3 Billion Bet to Reverse Aging
Latest article
Karman Stock’s Rally Turns Into an Earnings Test as Backlog Jumps and Valuation Bites
Karman Holdings shares closed up 6.2% at $62.48 on May 12, then fell 11% after hours following first-quarter results and a raised 2026 outlook. Q1 revenue jumped 51% to $151.2 million, net income reached $7.8 million, and backlog hit $1.0 billion. Adjusted EPS matched the $0.11 estimate. The company announced over $1 billion in new contingent demand commitments.
Velo3D Stock Jumps After Q1 Results Turn Margin Story Into a Real Test
Velo3D shares surged 24.7% to $17.53 in after-hours trading Tuesday after first-quarter revenue rose 48% to $13.8 million and net loss narrowed to $7.0 million. Gross margin improved to 17.2%. The company raised $50 million in April but remains loss-making, with a recent going-concern warning. Backlog stood near $30 million, with repeat orders above 70% of total.
Penguin Solutions Stock Gets a Fresh AI Memory Re-Rate, Even as Chip Tape Turns Rough
Penguin Solutions shares surged nearly 20% after hours to $52.85 following management remarks at a Needham investor conference and a target hike from Rosenblatt Securities. The move came despite fiscal Q2 net sales falling 6% year over year, though Integrated Memory revenue jumped 63%. CEO Kash Shaikh highlighted AI inference workloads driving memory demand. Trading volume topped 5 million shares.
